Bristol-Myers Squibb said it has a strategic partnership with Anthropic to provide its workforce with access to the Claude AI model [1].
This collaboration marks a significant shift in how the pharmaceutical giant intends to integrate generative artificial intelligence into its core operations. By embedding these tools into the daily workflows of its staff, the company aims to reduce the time and cost associated with bringing new medicines to market.
The partnership focuses on accelerating three primary stages of the pharmaceutical pipeline: drug discovery, development, and delivery [1], [2]. The company said it intends to leverage the generative AI capabilities of Claude to streamline day-to-day activities across its global operations [2], [3].
According to the company, more than 30,000 employees will have access to the Claude AI model [1]. This wide-scale deployment is designed to empower researchers and administrative staff to process complex data more efficiently — a move that analysts suggest could provide a competitive edge in a high-stakes industry.
BMS is based in the U.S. and the announcement was made via a U.S. press release on Wednesday, May 20, 2024 [1]. The market responded positively to the news, with the company's stock price rising following the announcement [2].
The move follows a broader trend of pharmaceutical companies investing in AI to solve biological puzzles that previously took years of manual trial and error. By using large language models, researchers can potentially identify promising drug candidates faster than traditional methods allow [3].
“More than 30,000 employees will have access to the Claude AI model.”
The integration of Claude AI at this scale suggests that Bristol-Myers Squibb is moving beyond experimental AI pilots toward a full-scale operational shift. If the company successfully reduces the drug development timeline, it could significantly lower the cost of R&D and increase the speed at which new therapies reach patients, potentially altering the valuation of its pipeline.
